Common Equity: The sum of all common equity items.
VistaGen Therapeutics, Inc. (VTGN) had Common Equity of $70.39M for the most recently reported fiscal year, ending 2025-03-31.
| Income Statement Financials | |
$0.49M |
|
$-51.42M |
|
-- |
|
$0.49M |
|
$56.46M |
|
$-55.97M |
|
$4.56M |
|
$-51.41M |
|
$-51.41M |
|
$-51.40M |
|
$-51.40M |
|
$-51.42M |
|
$-51.40M |
|
$-55.97M |
|
$-56.21M |
|
30.88M |
|
30.88M |
|
$-1.67 |
|
$-1.67 |
|
| Balance Sheet Financials | |
$82.08M |
|
$0.48M |
|
$2.27M |
|
$84.34M |
|
$12.61M |
|
-- |
|
$1.34M |
|
$13.95M |
|
|
Common Equity |
$70.39M |
$70.39M |
|
$70.39M |
|
29.00M |
|
| Cash Flow Statement Financials | |
$-42.10M |
|
$-13.15M |
|
$3.21M |
|
$119.17M |
|
$67.13M |
|
$-52.03M |
|
$4.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.51 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-11517.08% |
|
-11517.08% |
|
-11566.25% |
|
-10578.40% |
|
-10579.84% |
|
$-42.29M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-73.03% |
|
-73.03% |
|
-60.95% |
|
-73.03% |
|
$2.43 |
|
$-1.37 |
|
$-1.36 |
|